Similarly, in the SELECT (Semaglutide and cardiovascular outcomes in obesity without diabetes) trial, the same GLP-1 receptor agonist when administered to overweight or obese individuals with pre-existing cardiovascular conditions resulted in a reduction in the incidence of cardiovascular death, non-fatal MI, or nonfatal stroke (68) as well as a reduction in symptoms and physical limitations in obese individuals with heart failure and preserved ejection fraction (69). This evidence concerns the gene GLP1R and diabetes mellitus.